Breaking Barriers in Cancer Care: AI-Driven Second Opinions Without Limits
Introduction
Clear Diagnostix is on a mission to make expert cancer evaluations and second opinions accessible to anyone, anywhere. Every year, 34 million new cancer cases are expected globally, yet access to oncologists remains limited. In the U.S., patients face weeks-long delays, insurance hurdles, and costly out-of-pocket expenses, while internationally, many are forced to travel across borders just to consult a specialist. These barriers leave millions uncertain about their diagnosis, treatment options, and future—when time is critical. By leveraging AI-powered insights and connecting patients with top oncologists worldwide, Clear Diagnostix eliminates these roadblocks, providing faster, more affordable, and truly accessible second opinions from the comfort of home.
A Mission Driven by Experience and Expertise
Clear Diagnostix is led by a powerhouse team with diverse, complementary skills—bringing together a HealthTech innovator, a Silicon Valley executive, a community engagement expert, and a renowned medical oncologist. United by a shared passion for making patient care more accessible and affordable, we have lived the very challenges we are working to solve.
Our CEO’s daughter was misdiagnosed, and only a second opinion led to the correct diagnosis. Our Chief Engagement Officer was misdiagnosed with having a cysts—until a second opinion revealed it was Triple Negative Inflammatory Breast Cancer and saved her life. These experiences fuel our mission: ensuring every patient—no matter where they are—gets expert medical guidance when it matters most.
The Growing Need for Expert Second Opinions
Cancer diagnoses are rising by 500,000 cases each year, projected to reach 34 million annually. As the burden grows, the need for expert second opinions becomes more critical than ever. A second opinion can clarify diagnoses, optimize treatment plans, and empower patients with confidence in their care. Clear Diagnostix ensures that every patient—regardless of location—has access to expert-guided evaluations when they need them most.
The Challenges of Accessing a Second Opinion
Second opinions are often inaccessible. In the U.S., insurance restrictions, specialist referrals, and high costs create delays that patients can’t afford. Internationally, many must cross borders and navigate complex healthcare systems just to consult an oncologist. These barriers leave countless patients in limbo—uncertain about their diagnosis, treatment, and future—when every moment matters.
Revolutionizing Second Opinions with AI and Global Access
Clear Diagnostix is revolutionizing second opinions with a fully operational platform already delivering results. By combining AI-powered insights, a global network of top oncologists, and seamless digital access, we eliminate the barriers of referrals, insurance delays, and costly travel.
Patients can securely upload medical records through EHR portals, receive expert evaluations from world-class oncologists, and gain clarity on their treatment—all from the comfort of home. With our platform live and actively serving patients, this is not just an idea; it’s a proven solution in action.
In a $500 billion oncology market, Clear Diagnostix is a disruptive force—modernizing second opinions and making expert cancer evaluations truly accessible, scalable, and globally available.
Market Opportunity
The $500 billion global oncology market faces a critical gap in expert second opinions. Clear Diagnostix is addressing a $1.385 billion market opportunity, leveraging AI-powered insights and oncologist validation to make expert evaluations more accessible.
Our go-to-market strategy begins with breast cancer second opinions in the U.S. and Mexico, where demand is high. With 310,000 new cases annually in the U.S. and 55,000 in Mexico, we are targeting 90,000 to 155,000 patients in the U.S. and 20,000 to 27,000 in Mexico who actively seek second opinions. This strategic entry enables us to refine our platform before expanding into Malaysia, India, and Brazil, where access remains a challenge.
In the short term, we are targeting a $55M Serviceable Obtainable Market (SOM), focusing on high-income, English-speaking regions for private-pay adoption.
As we scale, Clear Diagnostix is set to disrupt the oncology market, bridging the gap between patients and top oncologists through a seamless, AI-powered second-opinion platform, making expert evaluations faster, more affordable, and accessible worldwide.
Go-to-Market Strategy
Clear Diagnostix is executing a partnership-driven GTM strategy, leveraging hospitals, cancer centers and non-profits that already serve patients needing second opinions. Instead of relying on costly direct-to-consumer (DTC) acquisition, we provide turnkey AI-driven solutions to organizations seeking to enhance patient care.
Beyond second opinions, many partners are interested in white-labeling or licensing our AI health companion, Kai, to offer real-time medical insights and continuous patient engagement. This B2B-first approach lowers customer acquisition costs (CAC) while enabling rapid scaling through trusted healthcare networks.
By integrating our AI and second-opinion services into existing patient workflows, Clear Diagnostix modernizes care, improves accessibility, and drives engagement—positioning us for fast adoption, high retention, and scalable revenue growth.
.jpeg)
Three-Tier Approach to Modernizing Second Opinions
Clear Diagnostix offers a three-tier product suite designed to provide patients with the right level of support at every stage of their healthcare journey.
At the core is Kai, our AI Health Companion, a white-label B2B solution that delivers real-time AI-driven medical insights, helping organizations enhance patient engagement. Kai not only educates patients but also serves as an entry point, seamlessly guiding them toward deeper evaluations when needed.
For those seeking more clarity, our AI-powered analysis with oncologist validation offers structured insights into medical records, providing expert-reviewed assessments without requiring a live consultation.
For patients needing a comprehensive second opinion, we connect them directly with top oncologists for a full case review and personalized treatment recommendations.
By combining AI-driven insights, oncologist expertise, and seamless B2B integrations, Clear Diagnostix is revolutionizing access to expert cancer evaluations—modernizing second opinions and transforming patient care worldwide.
Market Validation & Early Traction
Clear Diagnostix is gaining strong market validation with multiple partnerships, letters of interest, and growing patient engagement. Organizations recognize the demand for AI-powered second opinions and medical insights, and many are actively exploring white-label and licensing opportunities for our AI health companion, Kai.
Our pilot programs have demonstrated early traction, with patients already engaging with the platform. With key partnerships in place and growing interest from healthcare organizations, Clear Diagnostix is positioned for rapid adoption and scalable growth, reinforcing the need for an accessible, AI-driven second opinion platform in the oncology market.
ClearDx: What Sets Us Apart
Clear Diagnostix stands out by combining AI-driven insights with expert oncologist validation, ensuring patients receive accurate, timely, and affordable second opinions. Our proprietary AI models are trained on exclusive oncology datasets, enhancing diagnostic accuracy while streamlining case analysis for specialists.
Unlike traditional second-opinion services, ClearDx offers global access, connecting patients with top oncologists regardless of location, eliminating the need for travel and long wait times. Through our B2B partnerships and white-label licensing, we integrate seamlessly with healthcare organizations, enabling them to enhance patient engagement with AI-powered medical insights.
With a first-mover advantage in AI-assisted second opinions and a team combining healthtech innovation, Silicon Valley expertise, and leading oncology specialists, ClearDx is uniquely positioned to disrupt the industry. Our platform is scalable, cost-effective, and designed to remove barriers to expert cancer care worldwide.
Use of Funds
The funding will be strategically allocated to accelerate product development, market expansion, and operational scaling. A significant portion will go toward enhancing our AI capabilities, improving EHR integrations, and expanding our oncologist network to ensure seamless, expert-driven second opinions. Additionally, we will invest in B2B partnerships and patient acquisition efforts, targeting organizations that can rapidly integrate and scale our services while keeping customer acquisition costs low. Lastly, funds will support team growth and regulatory compliance, ensuring Clear Diagnostix is positioned for sustainable, long-term success in transforming global access to second opinions.
An Opportunity to Join Us
Clear Diagnostix is revolutionizing the way second opinions are delivered in the $500 billion oncology market, leveraging AI-powered insights, global oncologist networks, and seamless digital access to make expert cancer evaluations accessible to all.
What sets us apart? We are the first-mover in AI-assisted second opinions, combining cutting-edge technology with human expertise to eliminate barriers in healthcare. Our exclusive oncology-trained AI models, global accessibility, and scalable B2B partnerships position us as a disruptive force in the industry.
With a strong pipeline of partnerships, growing patient engagement, and proven demand, we are at a pivotal moment for expansion. This is an opportunity to join a company that is transforming cancer care, breaking geographical barriers, and modernizing second opinions for a global patient base.